Evaluation of Markers of Inflammation and Oxidative Stress in COPD Patients with or without Cardiovascular Comorbidities

Heart Lung and Circulation

Volumn 24, Issue 8, 2015, Pages 817-823

  Kaźmierczak, Marcin ^a   Ciebiada, Maciej ^b   Pekala Wojciechowska, Anna ^b   Pawłowski, Maciej ^b   Nielepkowicz Goździńska, Agnieszka ^b   Antczak, Adam ^b  

^a Asthma and Allergy ^*  (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cardiovascular disease; Chronic obstructive pulmonary disease; Heart failure; Inflammation; Isoprostane; Leukotriene

Indexed keywords

8 ISOPROSTANE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLUCOSE; INTERLEUKIN 8; LEUKOTRIENE B4; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; 8-EPI-PROSTAGLANDIN F2ALPHA; AUTACOID; IL8 PROTEIN, HUMAN; PROSTAGLANDIN F2 ALPHA;

AGED; ARTICLE; BODY MASS; BREATH ANALYSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; EXPERIMENTAL LOCOMOTOR ACTIVITY TEST; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MALE; OXIDATIVE STRESS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIX MINUTE WALK TEST; SPIROMETRY; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASES; EVALUATION STUDY; METABOLISM; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

AGED; BIOMARKERS; BREATH TESTS; CARDIOVASCULAR DISEASES; COMORBIDITY; DINOPROST; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-8; LEUKOTRIENE B4; MALE; MIDDLE AGED; OXIDATIVE STRESS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84938201689     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2015.01.019     Document Type: Article

References (45)

1. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555.
2. Agusti A.G., Noguera A., Sauleda J. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003, 21:347-360.
3. Sin D.D., Man S.F. Skeletal muscle weakness, reduced exercise tolerance and COPD: is systemic inflammation the missing link?. Thorax 2006, 61:1-3.
4. De Torres J.P., Cordoba-Lanus E., Lopez-Aguilar C., Muros de Fuentes M., Montejo de Garcini A., Aguirre-Jaime A., et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006, 27(5):902-907.
5. Car B.D., Meloni F., Luisetti M., Semenzato G., Gialdroni-Grassi G., Walz A. Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Crit Card Med 1994, 149:655-659.
6. Keatings V.M., Collins P.D., Scott D.M., Barnes P.J. Differences in interleukin-8 and tumour necrosis factor- alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996, 153:530-534.
7. Ko F.W., Lau C.Y., Leung T.F., Wong G.W., Lam C.W., Lai C.K., et al. Exhaled breath condensate levels of 8-isoprostane, growth related oncogene alpha and monocyte chemoattractant protein-1 in patients with chronic obstructive pulmonary disease. Respir Med 2006, 100(4):630-638.
8. Carpagnano G.E., Kharitonov S.A., Foschino-Barbaro M.P., Resta O., Gramiccioni E., Barnes P.J. Increased inflammatory markers in the exhaled breath condensate of cigarette smokers. Eur Respir J 2003, 21(4):589-593.
9. Montuschi P., Kharitonov S.A., Ciabottoni G., Barnes P.J. Exhaled leukotrienes and prostaglandins in COPD. Thorax 2003, 58(7):585-588.
10. Zalecenia Polskiego Towarzystwa Ftyzjopneumologicznego dotyczące wykonywania badań spirometrycznych. Pneumonologia i Alergologia Polska 2004; 72 Supplement 2.
11. Enright P.L. The six-minute walk test. Respir Care 2003, 48(8):783-785.
12. Hoffman P., Kasprzak J.D. Echokardiografia. Via Medica Gdansk 2004, 38-52.
13. Schena M, Clini E, A Errera D, Quadri A. Echo-Doppler evaluation of left ventricular impairment in chronic cor pulmonale. Chest 1996;109:1446-1451.
14. Miyahara Y., Ikeda S., Yoshinaga T., Yamaguchi K., Nishimura-Shirono E., Yamasa T., et al. Echocardiographic evaluation of right cardiac function in patients with chronic pulmonary disease. Jpn Heart J 2001, 42:483-493.
15. Weihs W., Picha R., Schuchlenz H., Harb S., Anelli-Monti B., Harnoncourt K. Echocardiographic grading of cor pulmonale in chronic lung diseases. Wien Klin Wochenschr 1995, 107:184-187.
16. Sin D.D., Anthonisen N.R., Soriano J.B., Agusti A.G. Mortality in COPD: role of comorbidities. Eur Respir J 2006, 28:1245-1257.
17. Mannino D.M., Thorn D., Swensen A., Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008, 32(4):962-969.
18. Sidney S., Sorel M., Quesenberry C.P., DeLuise C., Lanes S., Eisner M.D. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005, 128(4):2068-2075.
19. Anthonisen N.R., Connett J.E., Enright P.L., Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002, 166(3):333-339.
20. Keaney J.F., Larson M.G., Vasan R.S., Wilson P.W., Lipinska I., Corey D., et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003, 23:434-439.
21. Devaraj S., Hirany S.V., Burk R.F., Jialal I. Divergence between LDL oxidative susceptibility and urinary F(2)-isoprostanes as measures of oxidative stress in type 2 diabetes. Clin Chem 2001, 47:1974-1979.
22. Rutten F.H., Cramer M.J., Lammers J.W., Grobbee D.E., Hoes A.W. Heart failure and chronic obstructive pulmonary disease: an ignored combination?. Eur J Heart Fail 2006, 8(7):706-711.
23. Dahl M., Vestbo J., Lange P., Bojesen S.E., Tybjaerg-Hansen A., Nordestgaard B.G. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. A. J Respir Crit Care Med 2007, 175:250-255.
24. Vernooy J.H., Kucukaycan M., Jacobs J.A., Chavannes N.H., Buurman W.A., Dentener M.A., et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002, 166:1218-1224.
25. Kaźmierczak M., Ciebiada M., Pękala-Wojciechowska A., Pawłowski M., Pietras T., Antczak A. Correlation of inflammatory markers with echocardiographic parameters of left and right ventricular function in patients with chronic obstructive pulmonary disease and cardiovascular diseases. Pol Arch Med Wewn 2014, 124(6):290-297.
26. Libby P., Ridker P.M. Inflammation and atherosclerotic role of C-reactive protein in risk assessment. Am J Med 2004, 116:9-16.
27. Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R. Comparison of C-reactive protein and low density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Eng J Med 2002, 347(20):1557-1565.
28. Alonso-Martinez J.L., Llorente-Diez B., Echegaray-Agara M., Olaz-Preciado F., Urbieta-Echezarreta M., González-Arencibia C. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail 2002, 4(3):331-336.
29. Vassalle C., Botto N., Andreassi M.G., Berti S., Biagini A. Evidence for enhanced 8- isoprostane plasma levels, as index of oxidative stress in vivo, in patients with coronary artery disease. Coron Artery Dis 2003, 14:213-218.
30. Gross M., Steffes M., Jacobs D.R., Yu X., Lewis L., Lewis C.E., et al. Plasma F2-isoprostanes and coronary artery calcification: the CARDIA study. Clin Chem 2005, 51:125-131.
31. Nonaka-Sarukawa M., Yamamoto K., Aoki H., Takano H., Katsuki T., Ikeda U., et al. Increased urinary isoprostane excretion in patients with non ischaemic congestive heart failure: a marker of oxidative stress. Heart 2003, 89(8):871-874.
32. Malaia L.T., Ladnyi A.I. Pathogenetic and therapeutic significance of the angioprotective systems in patients with coronary arterisclerosis. Kardiologiia 1990, 30:5-9.
33. Takase B., Maruyama T., Kurita A., Uehata A., Nishioka T., Mizuno K., et al. Arachidonic acid metabolite in acute mycardial infarction. Angiology 1996, 47(7):649-661.
34. Damas J.K., Gullestad L., Ueland T., Solum N.O., Simonsen S., Frøland S.S., et al. CXC-chemokines, a new group of cytokines in congestive heart failure - possible role of platelets and monocytes. Cardivasc Res 2000, 45:428-436.
35. Mazurov V.I., Stvolov S.V., Linetskaia N.E., Baldueva I.A. Levels of anti-inflammatory cytokines interleukin-2, interleukin-8, and soluble interleukin-2 receptor in blood of patients with various forms of ischaemic heart disease. Ter Arkh 2001, 73:14-17.
36. Ito T., Ikeda U. Inflammatory cytokines and cardiovascular disease. Curr Drug Targets Inflamm Allergy 2003, 2:257-265.
37. Rothenbacher D., Muller-Scholze S., Herder C., Koenig W., Kolb H. Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers. Arterioscler Thromb Vasc Biol 2006, 26:194-199.
38. Musiał J., Undas A., Gajewski P., Jankowski M., Sydor W., Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 2001, 77(2-3):247-253.
39. Hitsumoto T., Lizuka T., Takahashi M., Nakamura K., Shimizu K., Satoh S., et al. A relationship between insulin resistence and reduction in oxidative stress in vivo by atorvastatin. J Cardiol 2004, 44(6):233-242.
40. Kaczmarek P., Sładek K., Skucha W., Rzeszutko M., Iwaniec T., Dziedzina S., et al. The influence of simvastatin on selected inflammatory markers in patients with chronic obstructive disease. Pol Arch of Int Med 2010, 120(1-2):11-17.
41. Lee T.M., Lin M.S., Chang N.C. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol 2008, 101(4):530-535.
42. Mancini G.B., Etminan M., Zhang B., Levesque L.E., FitzGerald J.M., Brophy J.M. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006, 47(12):2554-2560.
43. Broekhuizen R., Wouters E.F., Creutzberg E.C., Schols A.M. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006, 61:17-22.
44. Cirillo D.J., Agrawal Y., Cassano P.A. Lipids and pulmonary function in the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2002, 155(9):842-848.
45. Izquierdo J.L., Almonacid C., Parra T., Perez J. Systemic and lung inflammation in 2 phenotypes of chronic obstructive pulmonary disease. Arch Bronconeumol 2006, 42(7):332-337.